Premium
Validation of the RHL30 digital gene expression assay as a prognostic biomarker for relapsed Hodgkin lymphoma
Author(s) -
Calvente Lourdes,
TremblayLeMay Rosemarie,
Xu Wei,
Chan Fong Chun,
Hong Michael,
Zhang Tong,
Yhim HoYoung,
Kuruvilla John,
Crump Michael,
Kukreti Vishal,
Prica Anca,
Regier Dean,
Marra Marco A.,
Karsan Aly,
Steidl Christian,
Scott David W.,
Sabatini Peter,
Kridel Robert
Publication year - 2020
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.16777
Subject(s) - medicine , biomarker , oncology , lymphoma , transplantation , cohort , autologous stem cell transplantation , stem cell , hodgkin lymphoma , non hodgkin's lymphoma , biology , genetics , biochemistry
Summary Despite continuing improvements in the management of classical Hodgkin lymphoma (cHL), relapse remains associated with a risk of lymphoma‐related mortality. The biological composition of relapse tumour biopsies shows interpatient variability, which can be leveraged to design prognostic biomarkers. Here, we validated the RHL30 assay, a previously reported gene expression model in an independent cohort of 41 patients with relapsed cHL. Patients classified as high‐risk by the RHL30 assay had inferior failure‐free survival (FFS) after autologous stem cell transplantation (2‐year FFS 41% vs. 92%, P = 0·035). The RHL30 model is a robust biomarker that risk‐stratifies patients considered for autologous stem cell transplantation.